Tema ETFs’s Charles River Laboratories CRL Stock Holding History

Tema ETFs’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$158K	Hold	697	–	–	0.01%	540
2026 Q1	$120K	Buy	697 +567	+436%	+$105K	0.01%	518
2025 Q4	$25.9K	Buy	+130	New	+$23.6K	﹤0.01%	554

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Tema ETFs's CRL Position: Q2 2026 in Review

Tema ETFs held its Charles River Laboratories (CRL) position steady in Q2 2026 at 697 shares worth $158K. The position accounts for 0.01% of the portfolio, ranked #540.

Tema ETFs first reported a position in CRL in Q4 2025 and has held it in 3 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Tema ETFs held 697 shares of Charles River Laboratories worth $158K as of Q2 2026.
Tema ETFs left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up 0.01% of Tema ETFs's portfolio in Q2 2026, its #540 holding.
Tema ETFs first reported a position in Charles River Laboratories in Q4 2025 and has held it in 3 quarters since.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.